Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022
Research Letter

Mycobacterium mageritense Lymphadenitis in Child

Miguel García-BoyanoComments to Author , Fernando Baquero-Artigao, Carlos Toro, Marina Alguacil-Guillén, Fernando Lázaro-Perona, and Cristina Calvo
Author affiliations: Hospital Universitario La Paz, Madrid, Spain (M. García-Boyano, F. Baquero-Artigao, C. Toro, M. Alguacil-Guillén, A. Lázaro-Perona, C. Calvo); Translational Research Network of Pediatric Infectious Diseases, Madrid (F. Baquero-Artigao, C. Calvo); CIBERINFEC, Instituto de Salud Carlos III, Madrid (F. Baquero-Artigao, C. Calvo)

Cite This Article


Although human infections caused by Mycobacterium mageritense are rare, there are some case reports involving sinusitis, pneumonia, and hospital-acquired infections in adults. We report a case of lymphadenitis caused by M. mageritense in a child in Spain.

Mycobacterium mageritense was identified as a novel distinct species in 1997. Its name is derived from Magerit, the old Arabic name of Madrid, Spain, the source of most of the human sputum specimens from which it was first isolated (1). Five years later, cases of clinical disease caused by M. mageritense were reported in adults (2). We report a case of lymphadenitis caused by M. mageritense in a child in Spain.

A previously healthy boy, 2 years and 9 months of age, came to a pediatric clinic because of a 1-week history of swelling of the right submandibular lymph node. Physical examination showed lymph node swelling in the right submandibular region with red‒violet discolored skin. He did not had a fever, pain, or any other signs and symptoms. An ultrasound examination showed an enlarged submandibular lymph node 18 mm in diameter. Laboratory studies showed a leukocyte count of 9,220 cells/mm3 (reference range 4,800‒15,000 cells/mm3), a differential count of 42% neutrophils (reference range 55%‒70%), and a C-reactive protein level of <0.05 mg/dL (reference range <1‒0.5 mg/dL).

Three days later, he underwent fine-needle aspiration of the involved lymph node. Histopathologic analysis showed necrotizing granulomatous lymphadenitis. Acid-fast bacillus staining was negative. Therefore, a nontuberculous mycobacterial lymphadenitis was suspected and treatment with oral clarithromycin (7.5 mg/kg every 12 h) and ciprofloxacin (15 mg/kg every 12 h) was started.

A rapidly growing mycobacterium was isolated from the lymph node specimen after 6 days of incubation in liquid culture medium (BBL Mycobacteria Growth Indicator Tube; Becton Dickinson, It was identified as M. mageritense by using GenoType Mycobacterium CM version 2.0 (Hain Lifescience, Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonics, yielded a score of 2.4 for M. mageritense. Whole-genome sequencing was performed to confirm these findings (GenBank accession no. JAJJNE010000000).

Susceptibility testing using a microdilution technique showed a susceptible MIC for linezolid (8 μg/mL); an intermediate MIC for moxifloxacin (2 μg/mL), imipenem (8 μg/mL), and cefoxitin (32 μg/mL); and a resistant MIC for trimethoprim/sulfamethoxazole (>8/152 μg/mL), ciprofloxacin (>4 μg/mL), amikacin (>64 μg/mL), clarithromycin (>16 μg/mL), doxycycline (>16 μg/mL), and tobramycin (>16 μg/mL). Breakpoints were those suggested by the Clinical and Laboratory Standards Institute for rapidly growing mycobacteria (3).

Accordingly, 3 weeks after fine-needle aspiration was performed, clarithromycin was replaced by oral linezolid (10 mg/kg every 8 h). However, this change was promptly stopped because of intolerance to linezolid, and clarithromycin was given again. The enlarged lymph node gradually improved, and antimicrobial drug treatment was discontinued 11 weeks after initial prescription. The lymph node was reduced to <50% of its initial size. Complete excision of residual lymph node and scar tissue was performed 2 months later, leading to total resolution of the lymphadenitis.

The biochemical and drug susceptibility patterns of M. mageritense are relatively similar to the formerly known M. fortuitum third biovariant complex (1,2). It is not surprising that they also seem to have the same clinical spectrum (2). Although human infections caused by M. mageritense are rare, there are case reports involving sinusitis, pneumonia, and hospital-acquired infections, including catheter-related bloodstream infections, implantable cardioverter defibrillator-related infections, prosthetic valve endocarditis, and intrathecal catheter-related meningitis (2,4,5). Skin and soft tissue infections, including parotitis, furunculosis, and surgical site infections, have also been reported (4).

Mycobacteria are widespread in nature (1) and rapidly growing mycobacteria, such as M. mageritense, are ubiquitous in most municipal water supplies (6). Although M. mageritense has been isolated from cutaneous lesions of a tsunami survivor (7) and from 2 patients who received footbaths at the same nail salon (6), in most of these case reports, such as for our case, the source of contamination was unknown. Thus, M. mageritense is a rapidly growing mycobacteria that can cause granulomatous lymphadenitis in children. Clinicians should be aware of this bacteria during differential diagnoses.

Dr. García-Boyano is a doctoral candidate in pediatric infectious diseases at the Hospital Universitario La Paz, Madrid. His primary research interests are tropical medicine, HIV, and healthcare-associated infections.



We thank Jaime Esteban for providing assistance with antimicrobial drug susceptibility testing.



  1. Domenech  P, Jimenez  MS, Menendez  MC, Bull  TJ, Samper  S, Manrique  A, et al. Mycobacterium mageritense sp. nov. Int J Syst Bacteriol. 1997;47:53540. DOIPubMedGoogle Scholar
  2. Wallace  RJ Jr, Brown-Elliott  BA, Hall  L, Roberts  G, Wilson  RW, Mann  LB, et al. Clinical and laboratory features of Mycobacterium mageritense. J Clin Microbiol. 2002;40:29305. DOIPubMedGoogle Scholar
  3. Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing of Mycobacteria, Nocardia spp, and other aerobic Actonomycetes. CLSI supplement M62. Wayne (PA): The Institute; 2018.
  4. Okabe  T, Sasahara  T, Suzuki  J, Onishi  T, Komura  M, Hagiwara  S, et al. Mycobacterium mageritense parotitis in an immunocompetent adult. Indian J Microbiol. 2018;58:2832. DOIPubMedGoogle Scholar
  5. Kim  J, Seong  MW, Kim  EC, Han  SK, Yim  JJ. Frequency and clinical implications of the isolation of rare nontuberculous mycobacteria. BMC Infect Dis. 2015;15:9. DOIPubMedGoogle Scholar
  6. Gira  AK, Reisenauer  AH, Hammock  L, Nadiminti  U, Macy  JT, Reeves  A, et al. Furunculosis due to Mycobacterium mageritense associated with footbaths at a nail salon. J Clin Microbiol. 2004;42:18137. DOIPubMedGoogle Scholar
  7. Appelgren  P, Farnebo  F, Dotevall  L, Studahl  M, Jönsson  B, Petrini  B. Late-onset posttraumatic skin and soft-tissue infections caused by rapid-growing mycobacteria in tsunami survivors. Clin Infect Dis. 2008;47:e116. DOIPubMedGoogle Scholar


Cite This Article

DOI: 10.3201/eid2803.211486

Original Publication Date: February 07, 2022

Table of Contents – Volume 28, Number 3—March 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Miguel García-Boyano, C/Ginzo de Limia 55, 9°C, Madrid 28034, Spain

Send To

10000 character(s) remaining.


Page created: January 10, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.